Reddit Posts
Mentions
It’s been a strong couple weeks for IMRX !
IMRX - Incredible news from their last drug trial update. They said in the investor update that their drug was so effective at treating pancreatic cancer, that they were going to start testing it for treating multiple kinds of cancers.
I love IMRX, I've been holding an adding for a few weeks now. Their drug test results for their pancreatic cancer treatment was groundbreaking.
$IMRX $CNVS are all green and gaining
i made butt load of gains from IMRX, seems like you lost out on money lmao
IMRX - immuneering - lots of insider buying lately, really good news with phase 2 pancreatic cancer treatment results, phase 3 starting soon. I’m in it for 13,000 shares. One of my friends is a pharmaceutical rep for them, and he said most of the employees and their families have been buying stock the last few months. He said they know things about 2-3 weeks ahead of the general public. I’ll continue to update as new info comes out
I’m hood rich thanks to IMRX volatility over the past couple of weeks. One more dip and run and I’ll be swimming in hookers.
IMRX Not financial advice
News earlier on IMRX Not financial advice
IMRX not financial advice
IMRX Not financial advice
IMRX Not financial advice
IMRX Not financial advice
Certainly! Immuneering Corporation (IMRX) is currently trading at $2.04, showing a slight upward momentum with the 10-day SMA at $1.89 and the 30-day SMA at $2.01, indicating a potential bullish trend. The RSI values are moderate, suggesting neither overbought nor oversold conditions, while the MACD histogram is positive, supporting a short-term bullish outlook. Despite low trading volume today, the stock has shown resilience around the $2 mark, which could act as a psychological support level. Given the broader market’s cautious sentiment and mixed technical signals, IMRX might experience moderate volatility. For today’s session, consider a LONG position with an entry around $2.00, targeting $2.10 as the first price target and $2.20 as the second, with a stop loss at $1.90 to manage downside risk. Confidence in reaching the first target is moderate due to the current technical setup, while the second target carries lower confidence given external market pressures. Investors should remain vigilant of broader market movements and sector-specific news that could impact IMRX’s trajectory.
You mean like $IMRX, another one that gets “cross posted” a lot?
Is it true the rumours about a OPA against IMRX (Immuneering Corporation. ) ? It would make sense to buy now that its value is lower to secure the takeover bid premium?
Is it true the rumours about a OPA against IMRX (Immuneering Corporation. ) ? It would make sense to buy now that its value is lower to secure the takeover bid premium?
IMRX is a little-discussed biopharm company that is mid development of several cancer treatment drugs. 1 recently received orphan drug status from the FDA with further good news expected by year end. Currently trading at 2.14/share, most price targets for end of next year are 10-11$/share. I know it’s not a 100 bagger but it could be close to a 10 bagger
LODE: > Comstock Inc. (LODE) is poised for a potential breakout today, driven by its recent partnership with the National Renewable Energy Laboratory, which positions it as a key player in the sustainable aviation fuel sector. The stock has shown strong upward momentum, with the current price of $0.521 above its 10-day SMA of $0.476 and 8-day EMA of $0.465, indicating bullish sentiment. The RSI values are in the mid-60s, suggesting room for further upside without being overbought. The MACD histogram is positive, reinforcing the bullish trend. Given the broader market’s cautious optimism and LODE’s alignment with renewable energy trends, an entry at $0.52 is advisable. Target the first price at $0.55 with a high confidence level due to technical strength, and a second target at $0.58 with moderate confidence, considering potential profit-taking. Set a stop loss at $0.50 to manage downside risk. IMRX: > Immuneering Corporation (IMRX) is showing signs of potential upward momentum, with its current price at $2.49 and technical indicators suggesting a bullish trend. The 10-day SMA at $2.61 is above the current price, indicating a possible short-term rally, while the RSI levels are neutral, providing room for upward movement. The MACD histogram is slightly negative, but the proximity of the EMA values to the current price suggests consolidation before a breakout. Given the broader market’s cautious optimism, IMRX could benefit from sector rotation into biotech. For today’s session, consider entering around $2.50, with a first target at $2.70 and a second target at $2.85, setting a stop loss at $2.35. Confidence in reaching the first target is moderate due to recent volume spikes and technical alignment, while the second target carries lower confidence given potential resistance near $2.70. Stay vigilant for any news developments that could impact sentiment. JOBY: > Joby Aviation, Inc. (JOBY) is showing promising momentum, with its current price of $5.8982 above key moving averages, indicating a bullish trend. The recent investment from Toyota has bolstered investor confidence, despite broader industry challenges. Technical indicators such as the MACD and RSI suggest continued upward momentum, with the MACD histogram at 0.089 signaling strong buying pressure. Given the cautious optimism in the broader market, JOBY could benefit from sector-specific interest in innovative tech plays. For today’s session, consider entering around $5.90, with a first target of $6.20 and a second target of $6.50, supported by recent highs and volume spikes. Set a stop loss at $5.70 to manage downside risk. Confidence in reaching the first target is moderate, given the positive sentiment and technical setup, while the second target carries lower confidence due to potential profit-taking and market volatility
$IMRX IMRX Float 21M Short 1.5M = 7.2% SI I'm not a biotech expert but those I talk to say this is a sifnificant investment check yahoo on history finance.yahoo.com/news/immuneeri… $60M net cash, burns $13.5-15M/qtr. Co. says run rate to 2H '25. Avg TP of analysts > $15 8/7 Needham raises to $15 (l). 03/10 oppenheimer reiterates 25 price target Impressive representation from the analyst on cc for a $65M mkt cap co: Jefferies Morgan Stanley Piper Sandler Mizuho Needham Oppenheimer I didn't understand much of the CC but my 2 big takeaways: 1) CR's (complete responses) in pancreatic cancer (most deadly cancer) are extremely rare. 2) This is just the beginning of a news cycle. Expect new news before end of year and a load of analyst commentary
$IMRX IMRX Float 21M Short 1.5M = 7.2% SI I'm not a biotech expert but those I talk to say this is a sifnificant investment check yahoo on history finance.yahoo.com/news/immuneeri… $60M net cash, burns $13.5-15M/qtr. Co. says run rate to 2H '25. Avg TP of analysts > $15 8/7 Needham raises to $15 (l). 03/10 oppenheimer reiterates 25 price target Impressive representation from the analyst on cc for a $65M mkt cap co: Jefferies Morgan Stanley Piper Sandler Mizuho Needham Oppenheimer I didn't understand much of the CC but my 2 big takeaways: 1) CR's (complete responses) in pancreatic cancer (most deadly cancer) are extremely rare. 2) This is just the beginning of a news cycle. Expect new news before end of year and a load of analyst commentary
if u going to invest in medical suggest u look in to IMRX- phase 2 of pancreatic cancer positive results so far was previously trading at 7/8 now currently sits at 2.45 -3 FDA granted fast track 7 ratings 1 hold 4 buy 2 Strong Buy. price target is 15-25 by top analysts.
Guys if u going to invest in medical suggest u look in to IMRX- phase 2 of pancreatic cancer positive results so far was previously trading at 7/8 now currently sits at 2.45 -3 FDA granted fast track 7 ratings 1 hold 4 buy 2 S Buy price target is 15-25 by top analysts.
Similar to TNON. Shit just don’t make sense. All while IMRX comes out with stellar news and it’s just dripping along.
IMRX new pancreatic cancer drug would have saved him
RYDE UPC AND IMRX can fly today with volume
Don't miss the rocket today. $IMRX
$IMRX - Chief Scientific Officer is buying. I don't know what else can convince you to buy more. Great Clinical Positive results is coming today news